Beyond Traditional Pain Relief: A Review of Alternative Analgesics in Myocardial Infarction Patient Management

References

• Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77. doi:10.1093/eurheartj/ehx393.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2016;67(10):1235–50. doi:10.1016/j.jacc.2015.10.005.
   PubMed Web of Science ®Google Scholar
• Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM, Peacock WF, Pollack CV, Gibler WB, Peterson ED. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149(6):1043–9. doi:10.1016/j.ahj.2005.02.010.
   PubMed Web of Science ®Google Scholar
• Puymirat E, Lamhaut L, Bonnet N, Aissaoui N, Henry P, Cayla G, Cattan S, Steg G, Mock L, Ducrocq G, et al. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. Eur Heart J. 2016;37(13):1063–71. doi:10.1093/eurheartj/ehv567.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Kesh K, Singh PK, Sharma U, Chupikova I, Ramakrishnan S, Roy S. Morphine use induces gastric microbial dysbiosis driving gastric inflammation through TLR2 signalling which is attenuated by proton pump inhibition. Br J Pharmacol. 2023;180(12):1582–96. doi:10.1111/bph.16025.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Kesh K, Ramakrishnan S, Roy S. Opioid Use in Murine Model Results in Severe Gastric Pathology that May Be Attenuated by Proton Pump Inhibition. Am J Pathol. 2022;192(8):1136–50. doi:10.1016/j.ajpath.2022.04.005.
   PubMed Web of Science ®Google Scholar
• Khansari M, Sohrabi M, Zamani F. The useage of opioids and their adverse effects in gastrointestinal practice: a review. Middle East J Dig Dis. 2013;5(1):5–16.
   PubMedGoogle Scholar
• Nimmo WS, Heading RC, Wilson J, Tothill P, Prescott LF. Inhibition of gastric emptying and drug absorption by narcotic analgesics. Br J Clin Pharmacol. 1975;2(6):509–13. doi:10.1111/j.1365-2125.1975.tb00568.x.
   PubMed Web of Science ®Google Scholar
• Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, Stavrou K, Migliorini A, Antoniucci D, Tamburino C, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2014;8(1):e001593. doi:10.1161/CIRCINTERVENTIONS.114.001593.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Abiose A, Tangphao O, Blaschke TF, Hoffman BB. Morphine-induced venodilation in humans. Clin Pharmacol Ther. 1996;60(5):554–60. doi:10.1016/S0009-9236(96)90151-4.
   PubMed Web of Science ®Google Scholar
• Rosow CE, Moss J, Philbin DM, Savarese JJ. Histamine release during morphine and fentanyl anesthesia. Anesthesiology. 1982;56(2):93–6. doi:10.1097/00000542-198202000-00003.
   PubMed Web of Science ®Google Scholar
• Duarte GS, Nunes-Ferreira A, Rodrigues FB, Pinto FJ, Ferreira JJ, Costa J, Caldeira D. Morphine in acute coronary syndrome: systematic review and meta-analysis. BMJ Open. 2019;9(3):e025232. doi:10.1136/bmjopen-2018-025232.
   PubMed Web of Science ®Google Scholar
• Farag M, Spinthakis N, Srinivasan M, Sullivan K, Wellsted D, Gorog DA. Morphine analgesia pre-PPCI is associated with prothrombotic state, reduced spontaneous reperfusion and greater infarct size. Thromb Haemost. 2018;118(3):601–12. doi:10.1055/s-0038-1629896.
   PubMed Web of Science ®Google Scholar
• Hobl E-L, Stimpfl T, Ebner J, Schoergenhofer C, Derhaschnig U, Sunder-Plassmann R, Jilma-Stohlawetz P, Mannhalter C, Posch M, Jilma B. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014;63(7):630–5. doi:10.1016/j.jacc.2013.10.068.
   PubMed Web of Science ®Google Scholar
• Hobl E-L, Reiter B, Schoergenhofer C, Schwameis M, Derhaschnig U, Lang IM, Stimpfl T, Jilma B. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers. Clin Res Cardiol. 2016;105(4):349–55. doi:10.1007/s00392-015-0927-z.
   PubMed Web of Science ®Google Scholar
• Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37(3):245–52. doi:10.1093/eurheartj/ehv547.
   PubMed Web of Science ®Google Scholar
• Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61(15):1601–6. doi:10.1016/j.jacc.2013.01.024.
   PubMed Web of Science ®Google Scholar
• Parodi G, Bellandi B, Valenti R, Migliorini A, Marcucci R, Carrabba N, Giurlani L, Gensini GF, Abbate R, Antoniucci D. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. Am Heart J. 2014;167(6):909–14. doi:10.1016/j.ahj.2014.03.011.
   PubMed Web of Science ®Google Scholar
• Montalescot G, van ‘t Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016–27. doi:10.1056/NEJMoa1407024.
   PubMed Web of Science ®Google Scholar
• Parodi G, Xanthopoulou I, Bellandi B, Gkizas V, Valenti R, Karanikas S, Migliorini A, Angelidis C, Abbate R, Patsilinakos S, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015;65(5):511–2. doi:10.1016/j.jacc.2014.08.056.
   PubMed Web of Science ®Google Scholar
• Parodi G, Talanas G, Mura E, Canonico ME, Siciliano R, Guarino S, Marini A, Dossi F, Franca P, Raccis M, et al. Orodispersible ticagrelor in acute coronary syndromes: the TASTER study. J Am Coll Cardiol. 2021;78(3):292–4. doi:10.1016/j.jacc.2021.05.015.
   PubMed Web of Science ®Google Scholar
• Xanthopoulou I, Davlouros P, Tsigkas G, Koutsogiannis N, Patsilinakos S, Deftereos S, Hahalis G, Alexopoulos D. Factors affecting platelet reactivity 2 hours after P2Y12 receptor antagonist loading in primary percutaneous coronary intervention for ST-Elevation myocardial infarction - impact of pain-to-loading time. Circ J. 2016;80(2):442–9. doi:10.1253/circj.CJ-15-0495.
   PubMed Web of Science ®Google Scholar
• Canonico ME, Sanna GD, Siciliano R, Guarino S, Bellandi B, Scudiero F, Saba PS, Esposito G, Alexopoulos D, Parodi G, et al. Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes. Platelets. 2022;33(3):390–7. doi:10.1080/09537104.2021.1915973.
   PubMed Web of Science ®Google Scholar
• Cantor WJ, Tan M, Berwanger O, Lavi S, White HD, Nicolau JC, Dehghani P, Tajer CD, Lopes RD, Moia DDF, et al. Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: insights from the TREAT trial. Am Heart J. 2022;251:1–12. doi:10.1016/j.ahj.2022.05.005.
   PubMed Web of Science ®Google Scholar
• Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RP. Morphine and cardiovascular outcomes among patients with non-st-segment elevation acute coronary syndromes undergoing coronary angiography. J Am Coll Cardiol. 2020;75(3):289–300. doi:10.1016/j.jacc.2019.11.035.
   PubMed Web of Science ®Google Scholar
• Berwanger O, Nicolau JC, Carvalho AC, Jiang L, Goodman SG, Nicholls SJ, Parkhomenko A, Averkov O, Tajer C, Malaga G, et al. Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a randomized clinical trial. JAMA Cardiol. 2018;3(5):391–9. doi:10.1001/jamacardio.2018.0612.
   PubMed Web of Science ®Google Scholar
• Berwanger O, Nicolau JC, Carvalho AC, Jiang L, Goodman S, Nicholls SJ, Parkhomenko A, Averkov O, Tajer C, Malaga G, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. Am Heart J. 2018;202:89–96. doi:10.1016/j.ahj.2018.02.017.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Newby LK, Harrington RA, Gibson CM, Van de Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, et al. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome–study design and rationale. Am Heart J. 2005;149(6):994–1002. doi:10.1016/j.ahj.2005.03.029.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van ‘t Hof A, Berdan LG, Lee KL, Strony JT, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360(21):2176–90. doi:10.1056/NEJMoa0901316.
   PubMed Web of Science ®Google Scholar
• Courtney KR. Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther. 1975;195(2):225–36.
   PubMed Web of Science ®Google Scholar
• Masic D, Liang E, Long C, Sterk EJ, Barbas B, Rech MA. Intravenous Lidocaine for Acute Pain: a Systematic Review. Pharmacotherapy. 2018;38(12):1250–9. doi:10.1002/phar.2189.
   PubMed Web of Science ®Google Scholar
• Zhong J, Hu J, Mao L, Ye G, Qiu K, Zhao Y, Hu S. Efficacy of intravenous lidocaine for pain relief in the emergency department: A systematic review and meta-analysis. Front Med. 2021;8:706844. doi:10.3389/fmed.2021.706844.
   Web of Science ®Google Scholar
• Sun Y, Li T, Wang N, Yun Y, Gan TJ. Perioperative systemic lidocaine for postoperative analgesia and recovery after abdominal surgery: a meta-analysis of randomized controlled trials. Dis Colon Rectum. 2012;55(11):1183–94. doi:10.1097/DCR.0b013e318259bcd8.
   PubMed Web of Science ®Google Scholar
• Vahidi E, Shakoor D, Aghaie Meybodi M, Saeedi M. Comparison of intravenous lidocaine versus morphine in alleviating pain in patients with critical limb ischaemia. Emerg Med J. 2015;32(7):516–9. doi:10.1136/emermed-2014-203944.
   PubMed Web of Science ®Google Scholar
• Weinberg L, Peake B, Tan CO, Nikfarjam M. Pharmacokinetics and pharmacodynamics of lignocaine: A review. WJA. 2015;4(2):17. doi:10.5313/wja.v4.i2.17.
   Google Scholar
• Martí-Carvajal AJ, Simancas-Racines D, Anand V, Bangdiwala S. Prophylactic lidocaine for myocardial infarction. Cochrane Database Syst Rev. 2015;2015(8):CD008553. doi:10.1002/14651858.CD008553.pub2.
   PubMedGoogle Scholar
• Fernando H, Duong T, Huynh K, Noonan J, Shaw J, Duffy SJ, Nehme Z, Smith K, Myles PS, Meikle PJ, et al. Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. Eur Heart J. 2021;42(39):4025–36. doi:10.1093/eurheartj/ehab557.
   PubMed Web of Science ®Google Scholar
• Fernando H, Nehme Z, Milne C, O'Brien J, Bernard S, Stephenson M, Myles PS, Lefkovits J, Peter K, Brennan A, et al. LidocAine versus opioids in myocardial infarction: the AVOID-2 randomized controlled trial. Eur Heart J Acute Cardiovasc Care. 2023;12(1):2–11. doi:10.1093/ehjacc/zuac154.
   PubMed Web of Science ®Google Scholar
• Abbas A, Matthews GH, Brown IW, Shambrook JS, Peebles CR, Harden SP. Cardiac MR assessment of microvascular obstruction. Br J Radiol. 2015;88(1047):20140470. doi:10.1259/bjr.20140470.
   PubMed Web of Science ®Google Scholar
• Fleischman RJ, Frazer DG, Daya M, Jui J, Newgard CD. Effectiveness and safety of fentanyl compared with morphine for out-of-hospital analgesia. Prehosp Emerg Care. 2010;14(2):167–75. doi:10.3109/10903120903572301.
   PubMed Web of Science ®Google Scholar
• Ibrahim K, Shah R, Goli RR, Kickler TS, Clarke WA, Hasan RK, Blumenthal RS, Thiemann DR, Resar JR, Schulman SP, et al. Fentanyl delays the platelet inhibition effects of oral ticagrelor: full report of the PACIFY randomized clinical trial. Thromb Haemost. 2018;118(8):1409–18. doi:10.1055/s-0038-1666862.
   PubMed Web of Science ®Google Scholar
• Iglesias JF, Valgimigli M, Carbone F, Lauriers N, Masci PG, Degrauwe S. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: full results of the PERSEUS randomized trial. Cardiol J. 2022;29(4):591–600. doi:10.5603/CJ.a2022.0049.
   PubMed Web of Science ®Google Scholar
• Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology. 2013;21(3):201–32. doi:10.1007/s10787-013-0172-x.
   PubMed Web of Science ®Google Scholar
• Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis. 2000;31(Supplement_5):S202–S10. doi:10.1086/317520.
   PubMed Web of Science ®Google Scholar
• Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002;99(21):13926–31. doi:10.1073/pnas.162468699.
   PubMed Web of Science ®Google Scholar
• Högestätt ED, Jönsson BAG, Ermund A, Andersson DA, Björk H, Alexander JP, Cravatt BF, Basbaum AI, Zygmunt PM. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem. 2005;280(36):31405–12. doi:10.1074/jbc.M501489200.
   PubMed Web of Science ®Google Scholar
• Pickering G, Loriot MA, Libert F, Eschalier A, Beaune P, Dubray C. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin Pharmacol Ther. 2006;79(4):371–8. doi:10.1016/j.clpt.2005.12.307.
   PubMed Web of Science ®Google Scholar
• Mallet C, Daulhac L, Bonnefont J, Ledent C, Etienne M, Chapuy E, Libert F, Eschalier A. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain. 2008;139(1):190–200. doi:10.1016/j.pain.2008.03.030.
   PubMed Web of Science ®Google Scholar
• Charpentier S, Galinski M, Bounes V, Ricard-Hibon A, El-Khoury C, Elbaz M, Ageron F-X, Manzo-Silberman S, Soulat L, Lapostolle F, et al. Nitrous oxide/oxygen plus acetaminophen versus morphine in ST elevation myocardial infarction: open-label, cluster-randomized, non-inferiority study. Scand J Trauma Resusc Emerg Med. 2020;28(1):36. doi:10.1186/s13049-020-00731-y.
   PubMed Web of Science ®Google Scholar
• Bakhshaei MH, Homayounfar S, Roozbahani B, Malekpour M, Farhadian M. A Triple-Blinded Randomized Study to Evaluate the Effect of Acetaminophen and Morphine Sulfate on Pain Relief in MI-patients. Arch Anesthesiol Critical Care. 2021;7(2):63–8. doi:10.18502/aacc.v7i2.6297.
   Google Scholar
• Tavenier AH, Hermanides RS, Ottervanger JP, Tolsma R, van Beurden A, Slingerland RJ, ter Horst PGJ, Gosselink ATM, Dambrink J-HE, van Leeuwen MAH, et al. Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. Eur Heart J Cardiovasc Pharmacother. 2022;8(1):4–12. doi:10.1093/ehjcvp/pvaa095.
   PubMed Web of Science ®Google Scholar